PDF herunterladen
CC BY 4.0 · Thromb Haemost
DOI: 10.1055/a-2537-6037
Coagulation and Fibrinolysis

Modifications of the Prothrombin Active Site S4 Subpocket Confer Resistance to Dabigatran

Viola J.F. Strijbis  ‡   *
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
2   VarmX B.V., Leiden, The Netherlands
,
Ka Lei Cheung‡   *
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Dejvid Veizaj 
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Tessa Rutten
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Boris de Bruin
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Pieter H. Reitsma
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
2   VarmX B.V., Leiden, The Netherlands
,
Daniël Verhoef 
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
2   VarmX B.V., Leiden, The Netherlands
,
Mettine H.A. Bos 
1   Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands
› Institutsangaben Funding Health∼Holland, Top Sector Life Sciences & Health
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints


Abstract

Background

Direct anticoagulants inhibit coagulation serine proteases by reversibly engaging their active site with high affinity. By modifying the S4 active site subpocket of factor (F)Xa, we introduced inhibitor resistance while preserving catalytic activity. Given the homology between FXa and thrombin in active site architecture and direct anticoagulant binding, we have targeted the S4 subsite to introduce inhibitor resistance in (pro)thrombin.

Methods

Recombinant prothrombin variants were generated in which I174 was substituted or sequence R92-N98 was exchanged with that of human kallikrein-3.

Results

Specific prothrombin clotting activity of the variants was 6-fold (intrinsic clotting) to 10-fold (extrinsic clotting) reduced relative to wild-type prothrombin. Further analyses revealed that modification of the S4 subsite hampers fibrinogen and thrombomodulin-mediated protein C conversion by thrombin. Consistent with this, the thrombin variants displayed a reduced catalytic efficiency toward the peptidyl substrate used in thrombin generation assessments. The variants displayed a 2-fold reduced sensitivity for dabigatran relative to wild-type prothrombin, while argatroban inhibition was unaffected. Analyses using a purified component system revealed an up to 24-fold and 4-fold reduced IC50 for inhibition of thrombin by dabigatran and argatroban, respectively. Molecular dynamics (MD) simulations of both dabigatran-bound and unbound (apo) modified thrombin variants indicated these to comprise a larger inhibitor binding pocket relative to wild-type thrombin and display reduced inhibitor binding. As a net effect, (pro)thrombin variants with S4 subsite modifications supported detectable fibrin formation at therapeutic dabigatran concentrations.

Conclusion

Our findings provide proof-of-concept for the engineering of thrombin variants that are resistant to direct thrombin inhibitors by modulating the S4 subsite.

Keywords

anticoagulants - direct thrombin inhibitors - anticoagulant reversal agents - serine proteases - recombinant fusion proteins

Authors' Contribution

Da.V., V.J.F.S., and M.H.A.B. designed the study. K.L.C., De.V., T.R., and B.B. performed the research. V.J.F.S., De.V., K.L.C., and M.H.A.B. analyzed and interpreted data. V.J.F.S. and De.V. drafted the manuscript. Da.V. and M.H.A.B. critically revised the manuscript. All authors revised the manuscript, agreed with its content, and approved of submission.


* These authors contributed equally to this study.


Supplementary Material



Publikationsverlauf

Eingereicht: 09. April 2024

Angenommen: 11. Februar 2025

Accepted Manuscript online:
12. Februar 2025

Artikel online veröffentlicht:
24. März 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8 (11) 3467-3475
    CrossrefPubMedSuche in Google Scholar
  • 2 Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002; 102 (12) 4501-4524
    CrossrefPubMedSuche in Google Scholar
  • 3 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedSuche in Google Scholar
  • 4 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedSuche in Google Scholar
  • 5 Connolly SJ, Eikelboom J, Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
    CrossrefPubMedSuche in Google Scholar
  • 6 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedSuche in Google Scholar
  • 7 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedSuche in Google Scholar
  • 8 Cohen AT, Spiro TE, Büller HR. et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
    CrossrefPubMedSuche in Google Scholar
  • 9 Goldhaber SZ, Leizorovicz A, Kakkar AK. et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365 (23) 2167-2177
    CrossrefPubMedSuche in Google Scholar
  • 10 Schulman S, Kearon C, Kakkar AK. et al; RE-MEDY Trial Investigators, RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368 (08) 709-718
    CrossrefPubMedSuche in Google Scholar
  • 11 Cohen AT, Harrington RA, Goldhaber SZ. et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375 (06) 534-544
    CrossrefPubMedSuche in Google Scholar
  • 12 Bauersachs R, Berkowitz SD, Brenner B. et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedSuche in Google Scholar
  • 13 Büller HR, Prins MH, Lensin AW. et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedSuche in Google Scholar
  • 14 Roehrig S, Straub A, Pohlmann J. et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48 (19) 5900-5908
    CrossrefPubMedSuche in Google Scholar
  • 15 Pinto DJ, Orwat MJ, Koch S. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 2007; 50 (22) 5339-5356
    CrossrefPubMedSuche in Google Scholar
  • 16 Fischer PM. Design of small-molecule active-site inhibitors of the S1A family proteases as procoagulant and anticoagulant drugs. J Med Chem 2018; 61 (09) 3799-3822
    CrossrefPubMedSuche in Google Scholar
  • 17 Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E. Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. Eur J Haematol 2015; 95 (05) 389-404
    CrossrefPubMedSuche in Google Scholar
  • 18 Schreuder M, Reitsma PH, Bos MHA. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. Semin Thromb Hemost 2020; 46 (08) 986-998
    Thieme ConnectPubMedSuche in Google Scholar
  • 19 van Es N, De Caterina R, Weitz JI. Reversal agents for current and forthcoming direct oral anticoagulants. Eur Heart J 2023; 44 (20) 1795-1806
    CrossrefPubMedSuche in Google Scholar
  • 20 Pollack Jr CV, Reilly PA, Bernstein R. et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114 (01) 198-205
    PubMedSuche in Google Scholar
  • 21 Milling Jr TJ, Middeldorp S, Xu L. et al; ANNEXA-4 Investigators. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation 2023; 147 (13) 1026-1038
    CrossrefPubMedSuche in Google Scholar
  • 22 Verhoef D, Visscher KM, Vosmeer CR. et al. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Nat Commun 2017; 8 (01) 528
    CrossrefPubMedSuche in Google Scholar
  • 23 Schreuder M, Jourdi G, Veizaj D. et al. Minimally modified human blood coagulation factor X to bypass direct factor Xa inhibitors. J Thromb Haemost 2024; 22 (08) 2211-2226
    CrossrefPubMedSuche in Google Scholar
  • 24 Bos MH, Camire RM. Procoagulant adaptation of a blood coagulation prothrombinase-like enzyme complex in Australian elapid venom. Toxins (Basel) 2010; 2 (06) 1554-1567
    CrossrefPubMedSuche in Google Scholar
  • 25 Skala W, Utzschneider DT, Magdolen V. et al. Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity. J Biol Chem 2014; 289 (49) 34267-34283
    CrossrefPubMedSuche in Google Scholar
  • 26 Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4 (11) 876-890
    CrossrefPubMedSuche in Google Scholar
  • 27 Debela M, Magdolen V, Bode W, Brandstetter H, Goettig P. Structural basis for the Zn2+ inhibition of the zymogen-like kallikrein-related peptidase 10. Biol Chem 2016; 397 (12) 1251-1264
    CrossrefPubMedSuche in Google Scholar
  • 28 Lechtenberg BC, Murray-Rust TA, Johnson DJ. et al. Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. Blood 2013; 122 (16) 2777-2783
    CrossrefPubMedSuche in Google Scholar
  • 29 Toso R, Camire RM. Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized. J Biol Chem 2004; 279 (20) 21643-21650
    CrossrefPubMedSuche in Google Scholar
  • 30 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
    CrossrefPubMedSuche in Google Scholar
  • 31 Bloemen S, Kelchtermans H, Hemker HC. Thrombin generation in low plasma volumes. Thromb J 2018; 16: 10
    CrossrefPubMedSuche in Google Scholar
  • 32 Case DA, Cheatham III TE, Darden T. et al. The Amber biomolecular simulation programs. J Comput Chem 2005; 26 (16) 1668-1688
    CrossrefPubMedSuche in Google Scholar
  • 33 Case DA, Aktulga HM, Belfon L. et al. Amber 2022. University of California; 2022
    Suche in Google Scholar
  • 34 Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods 2022; 19 (06) 679-682
    CrossrefPubMedSuche in Google Scholar
  • 35 Jumper J, Evans R, Pritzel A. et al. Highly accurate protein structure prediction with AlphaFold. Nature 2021; 596 (7873) 583-589
    CrossrefPubMedSuche in Google Scholar
  • 36 Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 2015; 10 (05) 449-461
    CrossrefPubMedSuche in Google Scholar
  • 37 Miller III BR, McGee Jr TD, Swails JM, Homeyer N, Gohlke H, Roitberg AE. MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 2012; 8 (09) 3314-3321
    CrossrefPubMedSuche in Google Scholar
  • 38 Brandstetter H, Turk D, Hoeffken HW. et al. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol 1992; 226 (04) 1085-1099
    CrossrefPubMedSuche in Google Scholar
  • 39 Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45 (09) 1757-1766
    CrossrefPubMedSuche in Google Scholar
  • 40 Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007; 98 (02) 333-338
    PubMedSuche in Google Scholar
  • 41 Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996; 7 (06) 455-458
    CrossrefPubMedSuche in Google Scholar
  • 42 Kim JM, Noh J, Park JW. et al. Dabigatran acylglucuronide, the major metabolite of dabigatran, shows a weaker anticoagulant effect than dabigatran. Pharmaceutics 2022; 14 (02) 257
    CrossrefPubMedSuche in Google Scholar
  • 43 Davie EW, Kulman JD. An overview of the structure and function of thrombin. Semin Thromb Hemost 2006; 32 (Suppl. 01) 3-15
    Thieme ConnectPubMedSuche in Google Scholar
  • 44 Gale AJ, Griffin JH. Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins 2004; 54 (03) 433-441
    CrossrefPubMedSuche in Google Scholar
  • 45 Stojanovski BM, Pelc LA, Di Cera E. Role of the activation peptide in the mechanism of protein C activation. Sci Rep 2020; 10 (01) 11079
    CrossrefPubMedSuche in Google Scholar
  • 46 Ayala YM, Arosio D, Di Cera E. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR1 or protein C. Ann N Y Acad Sci 2001; 936: 456-458
    CrossrefPubMedSuche in Google Scholar
  • 47 Peacock RB, Davis JR, Markwick PRL, Komives EA. Dynamic consequences of mutation of tryptophan 215 in thrombin. Biochemistry 2018; 57 (18) 2694-2703
    CrossrefPubMedSuche in Google Scholar
  • 48 Sondag D, Verhoeven S, Löwik DWPM. et al. Activity sensing of coagulation and fibrinolytic proteases. Chemistry 2023; 29 (18) e202203473
    CrossrefPubMedSuche in Google Scholar
  • 49 Skejić J, Hodgson WC. Population divergence in venom bioactivities of elapid snake Pseudonaja textilis: role of procoagulant proteins in rapid rodent prey incapacitation. PLoS One 2013; 8 (05) e63988
    CrossrefPubMedSuche in Google Scholar
  • 50 Reza MA, Minh Le TN, Swarup S, Manjunatha Kini R. Molecular evolution caught in action: gene duplication and evolution of molecular isoforms of prothrombin activators in Pseudonaja textilis (brown snake). J Thromb Haemost 2006; 4 (06) 1346-1353
    CrossrefPubMedSuche in Google Scholar
  • 51 Bock PE, Panizzi P, Verhamme IM. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 2007; 5 (Suppl. 01) 81-94
    CrossrefPubMedSuche in Google Scholar
  • 52 Bauer CA, Brayer GD, Sielecki AR, James MN. Active site of alpha-lytic protease: enzyme-substrate interactions. Eur J Biochem 1981; 120 (02) 289-294
    CrossrefPubMedSuche in Google Scholar
  • 53 Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11 (01) 2-16
    CrossrefPubMedSuche in Google Scholar
  • 54 Posma JJ, Posthuma JJ, Spronk HM. Coagulation and non-coagulation effects of thrombin. J Thromb Haemost 2016; 14 (10) 1908-1916
    CrossrefPubMedSuche in Google Scholar
  • 55 Bos MHA, van't Veer C, Reitsma PH. Molecular biology and biochemistry of the coagulation factors and pathways of hemostasis. In: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DL. ed. Williams Hematology. 10th ed.. McGraw Hill; 2021: 2017-2050
    Suche in Google Scholar
  • 56 Cer RZ, Mudunuri U, Stephens R, Lebeda FJ. IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding. Nucleic Acids Res 2009; 37 (Web Server issue): W441-5
    PubMedSuche in Google Scholar